Recently Featured

STAT Investigates Alcohol Epidemic Responsible for 178,000 Annual Deaths in the U.S.

June 2, 2026
STAT has launched an investigative series titled “The Deadliest Drug,” revealing the alarming statistics surrounding excessive alcohol consumption, which claims the lives of 178,000 Americans each year. This series underscores a critical public health issue that has largely evaded comprehensive regulatory scrutiny, despite its significant contribution to disease, injury, and mortality rates. The context of…

To gain tariff exemptions, drugmakers must reveal US production plans

June 1, 2026
To secure an exemption from 100% tariffs on imported drugs to the U.S., companies that have not made Most Favored Nation (MFN) pricing deals with the government will be required to provide detailed information on their investment and production plans, according to documents released Wednesday by the Department of Commerce. This new requirement underscores the…

Create Medicines raises $122M to bolster in vivo CAR-T therapies

June 1, 2026
Create Medicines has successfully secured $122 million in funding, aimed at advancing its innovative pipeline of RNA-based CAR-T cell therapies targeting both cancer and autoimmune diseases. This significant investment underscores the growing confidence in the potential of CAR-T therapies, particularly those that leverage RNA technology to enhance efficacy and safety profiles. The funding will enable…

ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss

June 1, 2026
At the recent ECO 2026 conference, the ATTAIN-MAINTAIN trial results were unveiled, highlighting the efficacy of orforglipron in sustaining weight loss among obese and overweight adults. This trial is pivotal as it addresses a significant challenge in obesity management—maintaining weight loss over time. The data presented indicates that orforglipron not only aids in initial weight…

Ongoing Cases